217 related articles for article (PubMed ID: 18369692)
1. Is triple negative a prognostic factor in breast cancer?
Nishimura R; Arima N
Breast Cancer; 2008; 15(4):303-8. PubMed ID: 18369692
[TBL] [Abstract][Full Text] [Related]
2. Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up.
Malorni L; Shetty PB; De Angelis C; Hilsenbeck S; Rimawi MF; Elledge R; Osborne CK; De Placido S; Arpino G
Breast Cancer Res Treat; 2012 Dec; 136(3):795-804. PubMed ID: 23124476
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Role of p53 Immunohistochemical Status in Invasive Breast Cancer. A Retrospective Review of 1387 Cases With Luminal-Like/Her2 Negative Breast Tumors.
Dajti G; Serra M; Cisternino G; Ceccarelli C; Pellegrini A; Melina M; De Leo A; Santini D; Taffurelli M; Zanotti S
Oncologist; 2024 May; 29(5):384-391. PubMed ID: 37995311
[TBL] [Abstract][Full Text] [Related]
4. Prognosis and outcome of small (<=1 cm), node-negative breast cancer on the basis of hormonal and HER-2 status.
Amar S; McCullough AE; Tan W; Geiger XJ; Boughey JC; McNeil RB; Coppola KE; McLaughlin SA; Palmieri FM; Perez EA
Oncologist; 2010; 15(10):1043-9. PubMed ID: 20930097
[TBL] [Abstract][Full Text] [Related]
5. Loss of stromal caveolin-1 expression predicts poor clinical outcome in triple negative and basal-like breast cancers.
Witkiewicz AK; Dasgupta A; Sammons S; Er O; Potoczek MB; Guiles F; Sotgia F; Brody JR; Mitchell EP; Lisanti MP
Cancer Biol Ther; 2010 Jul; 10(2):135-43. PubMed ID: 20431349
[TBL] [Abstract][Full Text] [Related]
6. Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases?
Simmons C; Miller N; Geddie W; Gianfelice D; Oldfield M; Dranitsaris G; Clemons MJ
Ann Oncol; 2009 Sep; 20(9):1499-1504. PubMed ID: 19299408
[TBL] [Abstract][Full Text] [Related]
7. Prognostic correlations with the microbiome of breast cancer subtypes.
Banerjee S; Wei Z; Tian T; Bose D; Shih NNC; Feldman MD; Khoury T; De Michele A; Robertson ES
Cell Death Dis; 2021 Sep; 12(9):831. PubMed ID: 34482363
[TBL] [Abstract][Full Text] [Related]
8. Population and target considerations for triple-negative breast cancer clinical trials.
Hyslop T; Michael Y; Avery T; Rui H
Biomark Med; 2013 Feb; 7(1):11-21. PubMed ID: 23387481
[TBL] [Abstract][Full Text] [Related]
9. Role of androgen receptor expression in early stage ER+/PgR-/HER2- breast cancer.
Tagliaferri B; Quaquarini E; Palumbo R; Balletti E; Presti D; Malovini A; Agozzino M; Teragni CM; Terzoni A; Bernardo A; Villani L; Sottotetti F
Ther Adv Med Oncol; 2020; 12():1758835920958355. PubMed ID: 32994808
[TBL] [Abstract][Full Text] [Related]
10. Changes in Overall Survival over Time for Patients with de novo Metastatic Breast Cancer.
Iwase T; Shrimanker TV; Rodriguez-Bautista R; Sahin O; James A; Wu J; Shen Y; Ueno NT
Cancers (Basel); 2021 May; 13(11):. PubMed ID: 34071219
[TBL] [Abstract][Full Text] [Related]
11. Tumor-Associated Neutrophils in Breast Cancer Subtypes.
Soto-Perez-de-Celis E; Chavarri-Guerra Y; Leon-Rodriguez E; Gamboa-Dominguez A
Asian Pac J Cancer Prev; 2017 Oct; 18(10):2689-2693. PubMed ID: 29072393
[TBL] [Abstract][Full Text] [Related]
12. Evidence-based guidelines for managing patients with primary ER+ HER2- breast cancer deferred from surgery due to the COVID-19 pandemic.
Dowsett M; Ellis MJ; Dixon JM; Gluz O; Robertson J; Kates R; Suman VJ; Turnbull AK; Nitz U; Christgen M; Kreipe H; Kuemmel S; Bliss JM; Barry P; Johnston SR; Jacobs SA; Ma CX; Smith IE; Harbeck N
NPJ Breast Cancer; 2020; 6():21. PubMed ID: 32550266
[TBL] [Abstract][Full Text] [Related]
13. The evolvement of breast cancer therapies: What we have done and where all these head off.
Nurlaila I; Pambudi S
Saudi Med J; 2024 Apr; 45(4):331-340. PubMed ID: 38657992
[TBL] [Abstract][Full Text] [Related]
14. Attenuation of p53 mutant as an approach for treatment Her2-positive cancer.
Fedorova O; Daks A; Shuvalov O; Kizenko A; Petukhov A; Gnennaya Y; Barlev N
Cell Death Discov; 2020; 6():100. PubMed ID: 33083021
[TBL] [Abstract][Full Text] [Related]
15. Biological subtypes of breast cancer: current concepts and implications for recurrence patterns.
Cadoo KA; Fornier MN; Morris PG
Q J Nucl Med Mol Imaging; 2013 Dec; 57(4):312-21. PubMed ID: 24322788
[TBL] [Abstract][Full Text] [Related]
16. Pattern of metastatic spread in triple-negative breast cancer.
Dent R; Hanna WM; Trudeau M; Rawlinson E; Sun P; Narod SA
Breast Cancer Res Treat; 2009 May; 115(2):423-8. PubMed ID: 18543098
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of hypofractionated and normofractionated radiotherapy in a triple-negative breast cancer model.
Grosche S; Bogdanova NV; Ramachandran D; Lüdeking M; Stemwedel K; Christiansen H; Henkenberens C; Merten R
Front Oncol; 2022; 12():852694. PubMed ID: 36387199
[TBL] [Abstract][Full Text] [Related]
18. VEGF Overexpression Significantly Increases Nanoparticle-Mediated siRNA Delivery and Target-Gene Downregulation.
Tan S; Chen Z; Mironchik Y; Mori N; Penet MF; Si G; Krishnamachary B; Bhujwalla ZM
Pharmaceutics; 2022 Jun; 14(6):. PubMed ID: 35745832
[TBL] [Abstract][Full Text] [Related]
19. IL-6 Cytokine Family: A Putative Target for Breast Cancer Prevention and Treatment.
Felcher CM; Bogni ES; Kordon EC
Int J Mol Sci; 2022 Feb; 23(3):. PubMed ID: 35163731
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of Programmed Death-Ligand 1 Receptor mRNA as an Independent Negative Prognostic Factor for Triple Negative Breast Cancer.
Purwanto I; Heriyanto DS; Ghozali A; Widodo I; Dwiprahasto I; Aryandono T; Haryana SM
World J Oncol; 2020 Oct; 11(5):216-222. PubMed ID: 33117465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
